U.S. drug company Merck strikes deal with nonprofit to share COVID pill formula with poorer nations
U.S. drug company Merck has granted U.N.-backed nonprofit Medicines Patent Pool a royalty-free license for its experimental new COVID-19 drug, allowing Merck's treatment to be "manufactured and sold cheaply" in the world's poorest nations, reports The New York Times.
The deal — which is set-up in hopes of expanding the drug's availability, widening its manufacturing base, and potentially pushing down its price, per The Washington Post — permits companies in 105 countries, particularly in Africa and Asia, to sublicense the formula for the "promising" antiviral pill and begin making it for their own populations, per the Times. Earlier in October, Merck reported that the "easy-to-take pill" is "shown to reduce the risk of hospitalization and death in some cases," writes the Post.
Some treatment-access advocates have welcomed the new deal, which will hopefully right some of the lopsided COVID treatment access the world is seeing now.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"The Merck license is a very good and meaningful protection for people living in countries where more than half of the world's population lives," James Love, head of Knowledge Ecology International, told the Times. "It will make a difference."
Added Charles Gore, director of nonprofit Medicines Patent Pool: "This is hopefully going to make things a lot easier in terms of keeping people out of hospital and stopping people dying in low- and middle-income countries," he said.
What's more, so long as the WHO classifies COVID-19 as a public health emergency, neither Merck nor its partners — Ridgeback Biotherapeutics and Emory University — will receive royalties from drug sales under the agreement, per the Post.
Added Director of Public Citizen and MPP boardmember Peter Maybarduk: "This license will not solve everything, but it is a starting point and an example."
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
'Democrats now have a chance to present a vigorous, compelling case'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
What has Kamala Harris done as vice president?
In Depth It's not uncommon for the second-in-command to struggle to prove themselves in a role largely defined by behind-the-scenes work
By Theara Coleman, The Week US Published
-
How Black organizations quickly pivoted and mobilized for Kamala Harris
In the spotlight Harris has a shot at being the first Black woman to lead the Democratic ticket
By Theara Coleman, The Week US Published
-
What does Covid look like in 2024?
Today's Big Question Disease experts are calling for closer monitoring as new variant fuels rise in infections
By Chas Newkey-Burden, The Week UK Published
-
Blind people will listen to next week's total eclipse
Speed Read While they can't see the event, they can hear it with a device that translates the sky's brightness into music
By Peter Weber, The Week US Published
-
Melting polar ice is messing with global timekeeping
Speed Read Ice loss caused by climate change is slowing the Earth's rotation
By Peter Weber, The Week US Published
-
An amphibian that produces milk?
speed read Caecilians, worm-like amphibians that live underground, produce a milk-like substance for their hatchlings
By Peter Weber, The Week US Published
-
Jupiter's Europa has less oxygen than hoped
speed read Scientists say this makes it less likely that Jupiter's moon harbors life
By Peter Weber, The Week US Published
-
Why February 29 is a leap day
Speed Read It all started with Julius Caesar
By Peter Weber, The Week US Published
-
US spacecraft nearing first private lunar landing
Speed Read If touchdown is successful, it will be the first U.S. mission to the moon since 1972
By Peter Weber, The Week US Published
-
Scientists create 'meaty' rice for eco-friendly protein
Speed Read Korean scientists have invented a new hybrid food, consisting of beef muscle and fat cells grown inside grains of rice
By Peter Weber, The Week US Published